Literature DB >> 21895035

Pharmacometrics for regulatory decision making: status and perspective.

Efthymios Manolis1, Ralf Herold.   

Abstract

Mesh:

Year:  2011        PMID: 21895035     DOI: 10.2165/11594340-000000000-00000

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


× No keyword cloud information.
  3 in total

1.  Proposals for model-based paediatric medicinal development within the current European Union regulatory framework.

Authors:  Efthymios Manolis; Gérard Pons
Journal:  Br J Clin Pharmacol       Date:  2009-10       Impact factor: 4.335

Review 2.  Role of modeling and simulation in pediatric investigation plans.

Authors:  Efthymios Manolis; Tariq Eldirdiry Osman; Ralf Herold; Franz Koenig; Paolo Tomasi; Spiros Vamvakas; Agnes Saint Raymond
Journal:  Paediatr Anaesth       Date:  2011-01-18       Impact factor: 2.556

3.  Impact of pharmacometric analyses on new drug approval and labelling decisions: a review of 198 submissions between 2000 and 2008.

Authors:  Joo Yeon Lee; Christine E Garnett; Jogarao V S Gobburu; Venkatesh A Bhattaram; Satjit Brar; Justin C Earp; Pravin R Jadhav; Kevin Krudys; Lawrence J Lesko; Fang Li; Jiang Liu; Rajnikanth Madabushi; Anshu Marathe; Nitin Mehrotra; Christoffer Tornoe; Yaning Wang; Hao Zhu
Journal:  Clin Pharmacokinet       Date:  2011-10       Impact factor: 6.447

  3 in total
  8 in total

Review 1.  Role of modelling and simulation: a European regulatory perspective.

Authors:  Siv Jönsson; Anja Henningsson; Monica Edholm; Tomas Salmonson
Journal:  Clin Pharmacokinet       Date:  2012-02-01       Impact factor: 6.447

2.  Evaluation of the long-term durability and glycemic control of fasting plasma glucose and glycosylated hemoglobin for pioglitazone in Japanese patients with type 2 diabetes.

Authors:  Frances Stringer; Joost DeJongh; Kazuaki Enya; Emiko Koumura; Meindert Danhof; Kohei Kaku
Journal:  Diabetes Technol Ther       Date:  2014-12-22       Impact factor: 6.118

Review 3.  Applications of pharmacometrics in the clinical development and pharmacotherapy of anti-infectives.

Authors:  Ashit Trivedi; Richard E Lee; Bernd Meibohm
Journal:  Expert Rev Clin Pharmacol       Date:  2013-03       Impact factor: 5.045

4.  Regulatory modeling and simulation moves into the next gear in europe.

Authors:  P H van der Graaf
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-02-27

5.  The Role of Modeling and Simulation in Development and Registration of Medicinal Products: Output From the EFPIA/EMA Modeling and Simulation Workshop.

Authors:  E Manolis; S Rohou; R Hemmings; T Salmonson; M Karlsson; P A Milligan
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-02-27

6.  Basic concepts in population modeling, simulation, and model-based drug development.

Authors:  D R Mould; R N Upton
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2012-09-26

7.  CPT: Pharmacometrics and Systems Pharmacology.

Authors:  Piet H van der Graaf
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2012-09-26

8.  Model Informed Drug Development and Regulation in China: Challenges and Opportunities.

Authors:  Li Li; Hongcan Han; Jun Wang; Chunmin Wei; Yuzhu Wang; Min Li; Yu Zhou; Jinbo Yang
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2019-01-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.